Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126482862 | 12648286 | 2 | F | 201607 | 20160830 | 20160812 | 20160906 | EXP | US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-51521BP | BOEHRINGER INGELHEIM | 80.66 | YR | F | Y | 0.00000 | 20160906 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126482862 | 12648286 | 1 | PS | AGGRENOX | ASPIRINDIPYRIDAMOLE | 1 | Oral | DOSE PER APPLICATION: 25 MG/200 MG; DAILY DOSE: 50 MG/400 MG | Y | 504978 | 20884 | CAPSULE | BID | ||||||
| 126482862 | 12648286 | 2 | C | FELODIPINE. | FELODIPINE | 1 | Oral | 5 MG | 0 | 5 | MG | TABLET | QD | ||||||
| 126482862 | 12648286 | 3 | C | LOSARTAN POTASSIUM. | LOSARTAN POTASSIUM | 1 | Oral | 100 MG | 0 | 50 | MG | TABLET | BID | ||||||
| 126482862 | 12648286 | 4 | C | Metoprolol Susccinate | 2 | Oral | 50 MG | 0 | 50 | MG | TABLET | QD | |||||||
| 126482862 | 12648286 | 5 | C | SIMVASTATIN. | SIMVASTATIN | 1 | Oral | 40 MG | 0 | 40 | MG | TABLET | QD | ||||||
| 126482862 | 12648286 | 6 | C | TORSEMIDE. | TORSEMIDE | 1 | Oral | 10 MG | 0 | 10 | MG | TABLET | QD | ||||||
| 126482862 | 12648286 | 7 | C | KLOR-CON | POTASSIUM CHLORIDE | 1 | Oral | DOSE PER APPLICATION/DAILY DOSE: M10MG | 0 | TABLET | QD | ||||||||
| 126482862 | 12648286 | 8 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 81 MG | 0 | 81 | MG | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126482862 | 12648286 | 1 | Antiplatelet therapy |
| 126482862 | 12648286 | 2 | Hypertension |
| 126482862 | 12648286 | 3 | Product used for unknown indication |
| 126482862 | 12648286 | 4 | Hypertension |
| 126482862 | 12648286 | 5 | Blood cholesterol increased |
| 126482862 | 12648286 | 6 | Hypertension |
| 126482862 | 12648286 | 7 | Supplementation therapy |
| 126482862 | 12648286 | 8 | Anticoagulant therapy |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126482862 | 12648286 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126482862 | 12648286 | Cerebrovascular accident | |
| 126482862 | 12648286 | Drug ineffective | |
| 126482862 | 12648286 | Headache |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126482862 | 12648286 | 1 | 201501 | 20160707 | 0 | |
| 126482862 | 12648286 | 2 | 201503 | 0 | ||
| 126482862 | 12648286 | 3 | 2008 | 0 | ||
| 126482862 | 12648286 | 4 | 2008 | 0 | ||
| 126482862 | 12648286 | 5 | 2008 | 0 | ||
| 126482862 | 12648286 | 6 | 2008 | 0 | ||
| 126482862 | 12648286 | 7 | 2008 | 0 | ||
| 126482862 | 12648286 | 8 | 201508 | 0 |